Hepatitis, Autoimmune
13
1
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
7.7%
1 terminated out of 13 trials
66.7%
-19.8% vs benchmark
31%
4 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (13)
Swiss Autoimmune Hepatitis Cohort Study
Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH
Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis
Study of the Clinical Features of Autoimmune Hepatitis
Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome
Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy
Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis
Phase II AutoImmune Hepatitis
Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis
CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS
Autoimmune Hepatitis Study